arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Scholar Rock Holding Corp

SRRK
$52.94 ▲ +0.25 (+0.46%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
37 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

Scholar Rock Holding Corp faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.7B
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -17.1%
FCF / Share $-0.65
Trailing P/E
Price / Book 22.8x
FCF Yield
Debt / Equity 0.71
info Valuation on last close. End-of-day price, Aug 7, 2026.

37-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-105.51M
↓ -41.2%
Operating Margin Operating profit as % of sales
-20.9%
↑ +95.8%
FCF / Share Free cash flow per share
$-0.65
↑ +8.5%
Long-Term Debt Long-term obligations
$196.61M
↑ +97.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
4
Financial Health
36
Cash Quality
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 37 quarters